Risk analysis in patients with and without metabolic syndrome
OwnerGeorg Hess, Dietmar Zdunek +1inventors
InventorsGeorg Hess, Dietmar Zdunek, Andrea Horsch
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for identifying a subject being susceptible to a metabolic syndrome related therapy based on determining the amounts of adiponectin, retinol binding protein 4, and proinsulin in a sample of a subject, and comparing the thus determined amounts to suitable reference amounts. Moreover, the present invention relates to a method for predicting the risk of developing a metabolic syndrome in an apparently healthy subject based on determining the aforementioned markers in a sample from the subject. Also encompassed by the present invention are kits and devices adapted to carry out the methods of the present invention.
Claims13
A method for identifying susceptibility of a subject to a metabolic syndrome related therapy, wherein the subject has not developed a metabolic syndrome, the method comprising the steps of:
- determining amounts of adiponectin, retinol binding protein 4 (RBP4), and proinsulin in a sample from the subject, and
- identifying the subject's susceptibility to a metabolic syndrome related therapy by comparing the amounts of adiponectin, RBP4, and proinsulin determined to reference amounts for adiponectin, RBP4, and proinsulin, respectively.
A method for predicting a risk of developing a metabolic syndrome in a subject who is apparently healthy with respect to a metabolic syndrome, the method comprising the steps of:
- determining amounts in a sample from the subject, and
- predicting the subject's risk of developing a metabolic syndrome by comparing the determined amounts of adiponectin, retinol binding protein (RBP4), and proinsulin to reference amounts for adiponectin, RBP4, and proinsulin.
Dependencies are inferred from the claim text.